Here are the 10-K annual reports from Edesa Biotech, Inc. (EDSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EDSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDSA filings page.
Edesa Biotech, Inc. files its annual report describing a biopharmaceutical company focused on inflammatory and immune-related diseases. Its lead respiratory candidate EB05 (paridiprubart) showed positive Phase 3 results in acute respiratory distress syndrome, with 28-day mortality of 39% on EB05 plus standard of care versus 52% on placebo, an absolute survival improvement of 13%, and a similar 13% benefit at 60 days, alongside a generally well-tolerated safety profile. EB05 is also being studied in a U.S. government-funded Phase 2 platform trial and backed by a Canadian Strategic Innovation Fund commitment of up to C$23 million, including up to C$5.75 million that is not repayable.
In medical dermatology, Edesa is advancing EB06, an anti-CXCL10 antibody for vitiligo, toward a Phase 2 trial in approximately 150 patients and is seeking partners for EB01, a Phase 3-ready topical therapy for allergic contact dermatitis. As of March 31, 2025, nonaffiliates held 5,728,786 of 7,022,678 common shares, with an aggregate market value of $13,978,238, and 8,333,823 common shares were outstanding as of December 12, 2025.